nach oben

Journal of Interventional Cardiac Electrophysiology

Erschienen in:

01.10.2008

New drugs for atrial fibrillation

verfasst von: Matthias Hammwöhner, Jan Smid, Uwe Lendeckel, Andreas Goette

Erschienen in: Journal of Interventional Cardiac Electrophysiology | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. Epidemiologic studies suggest that the number of patients with AF will triple in the next 30 years, and therefore, its impact on medical and economic issues will further increase. Due to the limited efficacy and significant side effects of antiarrhythmic drugs, much effort has been made to develop alternative pharmacologic treatments for AF. Novel approaches include new antiarrhythmic drugs and novel drug targets involved in molecular, proarrhythmogenic, atrial remodeling. Furthermore, novel anticoagulants are now clinically studied. This review briefly summarizes new developments in the pharmacotherapy for AF.

Fuster, V., Ryden, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., et al. (2006). ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation, 114, e257–e354.PubMedCrossRef

Kannel, W. B., Abbott, R. D., Savage, D. D., & McNamara, P. M. (1982). Epidemiologic features of chronic atrial fibrillation: The Framingham study. New England Journal of Medicine, 306, 1018–1022.PubMed

Ravens, U., Wettwer, E., Schotten, U., Wessel, R., & Dobrev, D. (2006). [New antiarrhythmic drugs for therapy of atrial fibrillation: I. Ion channel blockers]. Herzschrittmachertherapie & Elektrophysiologie, 17, 64–72.CrossRef

Bosch, R. F., & Nattel, S. (2002). Cellular electrophysiology of atrial fibrillation. Cardiovascular Research, 54, 259–269.PubMedCrossRef

de Haan, S., Greiser, M., Harks, E., Blaauw, Y., van Hunnik, A., Verheule, S., et al. (2006). AVE0118, blocker of the transient outward current (I(to)) and ultrarapid delayed rectifier current (I(Kur)), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat. Circulation, 114, 1234–1242.PubMedCrossRef

Blaauw, Y., Schotten, U., van, H. A., Neuberger, H. R., & Allessie, M. A. (2007). Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat. Cardiovascular Research, 75, 89–98.PubMedCrossRef

Lofberg, L., Jacobson, I., & Carlsson, L. (2006). Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: A comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro. Europace, 8, 549–557.PubMedCrossRef

Goldstein, R. N., Khrestian, C., Carlsson, L., & Waldo, A. L. (2004). Azd7009: A new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. Journal of Cardiovascular Electrophysiology, 15, 1444–1450.PubMedCrossRef

Gogelein, H., Brendel, J., Steinmeyer, K., Strubing, C., Picard, N., Rampe, D., et al. (2004). Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naunyn-Schmiedeberg’s Archives of Pharmacology, 370, 183–192.PubMed

10.

Wirth, K. J., Brendel, J., Steinmeyer, K., Linz, D. K., Rutten, H., & Gogelein, H. (2007). In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231. Journal of Cardiovascular Pharmacology, 49, 197–206.PubMedCrossRef

11.

Roy, D., Rowe, B. H., Stiell, I. G., Coutu, B., Ip, J. H., Phaneuf, D., et al. (2004). A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. Journal of the American College of Cardiology, 44, 2355–2361.PubMedCrossRef

12.

Touboul, P., Brugada, J., Capucci, A., Crijns, H. J., Edvardsson, N., & Hohnloser, S. H. (2003). Dronedarone for prevention of atrial fibrillation: A dose-ranging study. European Heart Journal, 24, 1481–1487.PubMedCrossRef

13.

Ausma, J., Wijffels, M., Thone, F., Wouters, L., Allessie, M., & Borgers, M. (1997). Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation, 96, 3157–3163.PubMed

14.

Frustaci, A., Chimenti, C., Bellocci, F., Morgante, E., Russo, M. A., & Maseri, A. (1997). Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation, 96, 1180–1184.PubMed

15.

Goette, A., Juenemann, G., Peters, B., Klein, H. U., Roessner, A., Huth, C., et al. (2002). Determinants and consequences of atrial fibrosis in patients undergoing open heart surgery. Cardiovascular Research, 54, 390–396.PubMedCrossRef

16.

Goette, A., & Lendeckel, U. (2004). Nonchannel drug targets in atrial fibrillation. Pharmacology & Therapeutics, 102, 17–36.CrossRef

17.

Nattel, S. (2002). New ideas about atrial fibrillation 50 years on. Nature, 415, 219–226.PubMedCrossRef

18.

Kjolbye, A. L., Knudsen, C. B., Jepsen, T., Larsen, B. D., & Petersen, J. S. (2003). Pharmacological characterization of the new stable antiarrhythmic peptide analog Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2 (ZP123): In vivo and in vitro studies. Journal of Pharmacology and Experimental Therapeutics, 306, 1191–1199.PubMedCrossRef

19.

Aonuma, S., Kohama, Y., Akai, K., Komiyama, Y., Nakajima, S., Wakabayashi, M., et al. (1980). Studies on heart. XIX. Isolation of an atrial peptide that improves the rhythmicity of cultured myocardial cell clusters. Chemical and Pharmaceutical Bulletin (Tokyo), 28, 3332–3339.

20.

Eloff, B. C., Gilat, E., Wan, X., & Rosenbaum, D. S. (2003). Pharmacological modulation of cardiac gap junctions to enhance cardiac conduction: Evidence supporting a novel target for antiarrhythmic therapy. Circulation, 108, 3157–3163.PubMedCrossRef

21.

Xing, D., Kjolbye, A. L., Nielsen, M. S., Petersen, J. S., Harlow, K. W., Holstein-Rathlou, N. H., et al. (2003). ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs. Journal of Cardiovascular Electrophysiology, 14, 510–520.PubMedCrossRef

22.

Shiroshita-Takeshita, A., Sakabe, M., Haugan, K., Hennan, J. K., & Nattel, S. (2007). Model-dependent effects of the gap junction conduction-enhancing antiarrhythmic peptide rotigaptide (ZP123) on experimental atrial fibrillation in dogs. Circulation, 115, 310–318.PubMedCrossRef

23.

Vest, J. A., Wehrens, X. H., Reiken, S. R., Lehnart, S. E., Dobrev, D., Chandra, P., et al. (2005). Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation, 111, 2025–2032.PubMedCrossRef

24.

Kumagai, K., Nakashima, H., Gondo, N., & Saku, K. (2003). Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model. Journal of Cardiovascular Electrophysiology, 14, 880–884.PubMedCrossRef

25.

Carnes, C. A., Chung, M. K., Nakayama, T., Nakayama, H., Baliga, R. S., Piao, S., et al. (2001). Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circulation Research, 89, E32–E38.PubMedCrossRef

26.

Dudley Jr., S. C., Hoch, N. E., McCann, L. A., Honeycutt, C., Diamandopoulos, L., Fukai, T., et al. (2005). Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: Role of the NADPH and xanthine oxidases. Circulation, 112, 1266–1273.PubMedCrossRef

27.

Mihm, M. J., Yu, F., Carnes, C. A., Reiser, P. J., McCarthy, P. M., Van Wagoner, D. R., et al. (2001). Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation, 104, 174–180.PubMed

28.

Shiroshita-Takeshita, A., Schram, G., Lavoie, J., & Nattel, S. (2004). Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation, 110, 2313–2319.PubMedCrossRef

29.

Patti, G., Chello, M., Candura, D., Pasceri, V., D’Ambrosio, A., Covino, E., et al. (2006). Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation, 114, 1455–1461.PubMedCrossRef

30.

Dernellis, J., & Panaretou, M. (2004). Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. European Heart Journal, 25, 1100–1107.PubMedCrossRef

31.

Halonen, J., Halonen, P., Jarvinen, O., Taskinen, P., Auvinen, T., Tarkka, M., et al. (2007). Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: A randomized controlled trial. JAMA, 297, 1562–1567.PubMedCrossRef

32.

van der Hooft, C. S., Heeringa, J., Brusselle, G. G., Hofman, A., Witteman, J. C., Kingma, J. H., et al. (2006). Corticosteroids and the risk of atrial fibrillation. Archives of Internal Medicine, 166, 1016–1020.PubMedCrossRef

33.

Goette, A., Staack, T., Rocken, C., Arndt, M., Geller, J. C., Huth, C., et al. (2000). Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. Journal of the American College of Cardiology, 35, 1669–1677.PubMedCrossRef

34.

Goette, A., Arndt, M., Rocken, C., Spiess, A., Staack, T., Geller, J. C., et al. (2000). Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation, 101, 2678–2681.PubMed

35.

Li, D., Fareh, S., Leung, T. K., & Nattel, S. (1999). Promotion of atrial fibrillation by heart failure in dogs: Atrial remodeling of a different sort. Circulation, 100, 87–95.PubMed

36.

Kumagai, K., Nakashima, H., Urata, H., Gondo, N., Arakawa, K., & Saku, K. (2003). Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. Journal of the American College of Cardiology, 41, 2197–2204.PubMedCrossRef

37.

Goette, A., Hoffmanns, P., Enayati, W., Meltendorf, U., Geller, J. C., & Klein, H. U. (2001). Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. American Journal of Cardiology, 88, 906–909 A8.PubMedCrossRef

38.

Zannad, F., Alla, F., Dousset, B., Perez, A., & Pitt, B. (2000). Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the randomized aldactone evaluation study (RALES). Rales investigators. Circulation, 102, 2700–2706.PubMed

39.

Goette, A., Bukowska, A., Lendeckel, U., Erxleben, M., Hammwohner, M., Strugala, D., et al. (2008). Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression. Circulation, 117, 732–742.PubMedCrossRef

40.

Hammwöhner, M., Ittenson, A., Dierkes, J., Bukowska, A., Klein, H. U., Lendeckel, U., et al. (2007). Platelet expression of CD40/CD40 ligand and its relation to inflammatory markers and adhesion molecules in patients with atrial fibrillation. Experimental Biology and Medicine (Maywood, N.J.), 232, 581–589.

41.

Eriksson, B. I., & Quinlan, D. J. (2006). Oral anticoagulants in development: Focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs, 66, 1411–1429.PubMedCrossRef

42.

Weitz, J. I., & Bates, S. M. (2005). New anticoagulants. Journal of Thrombosis and Haemostasis, 3, 1843–1853.PubMedCrossRef

43.

Hammwöhner, M., D’Alessandro, A., Wolfram, O., & Goette, A. (2007). New pharmacologic approaches to prevent thromboembolism in patients with atrial fibrillation. Current Vascular Pharmacology, 5, 211–219.PubMedCrossRef

44.

Hammwöhner, M., D’Alessandro, A., Dobrev, D., Kirchhof, P., & Goette, A. (2006). [New antiarrhythmic drugs for therapy of atrial fibrillation: II. Non-ion channel blockers]. Herzschrittmachertherapie & Elektrophysiologie, 17, 73–80.CrossRef

45.

Goette, A., Bukowska, A., & Lendeckel, U. (2007). Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling). Current Opinion in Pharmacology, 7, 219–224.PubMedCrossRef

46.

Monroe, D. M., Hoffman, M., & Roberts, H. R. (2002). Platelets and thrombin generation. Arteriosclerosis, Thrombosis, and Vascular Biology, 22, 1381–1389.PubMedCrossRef

Titel: New drugs for atrial fibrillation
verfasst von: Matthias Hammwöhner
Jan Smid
Uwe Lendeckel
Andreas Goette
Publikationsdatum: 01.10.2008
Verlag: Springer US
Erschienen in: Journal of Interventional Cardiac Electrophysiology / Ausgabe 1/2008
Print ISSN: 1383-875X
Elektronische ISSN: 1572-8595
DOI: https://doi.org/10.1007/s10840-008-9278-2

Neu im Fachgebiet Kardiologie

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Chronisches Koronarsyndrom: Gefahr von Hospitalisierung wegen Herzinsuffizienz

06.05.2024 Herzinsuffizienz Nachrichten

Obwohl ein rezidivierender Herzinfarkt bei chronischem Koronarsyndrom wahrscheinlich die Hauptsorge sowohl der Patienten als auch der Ärzte ist, sind andere Ereignisse womöglich gefährlicher. Laut einer französischen Studie stellt eine Hospitalisation wegen Herzinsuffizienz eine größere Gefahr dar.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2008

Ablation of permanent AF

Advances in remote monitoring of implantable pacemakers, cardioverter defibrillators and cardiac resynchronization therapy systems

New antiarrhythmic drugs for atrial fibrillation: Focus on dronedarone and vernakalant

The future of implantable defibrillator and cardiac resynchronization therapy trials